ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "clinical trial"

  • Abstract Number: 2352 • ACR Convergence 2025

    Long-Term Uveitis Rates with Bimekizumab Treatment Across Pooled Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update

    Martin Rudwaleit1, Irene E. van der Horst-Bruinsma2, Floris A. van Gaalen3, Nigil Haroon4, Lianne S. Gensler5, Myriam Manente6, Chetan Prajapati7, Katy White7, Atul Deodhar8 and Matthew A. Brown9, 1Bielefeld University, Medical School and University Medical Centre OWL, Klinikum Bielefeld, Department of Rheumatology, Bielefeld, Germany, 2Department of Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada, 5Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 6UCB, Braine-L'Alleud, Belgium, 7UCB, Slough, United Kingdom, 8Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, 9Genomics England, London, United Kingdom

    Background/Purpose: Uveitis is a common extra-musculoskeletal manifestation in patients (pts) with spondyloarthritis (SpA); incidence varies with SpA type and disease duration.1–3 IL-17 has been implicated…
  • Abstract Number: 2083 • ACR Convergence 2025

    Evaluation of a Parent-Trial as a Run-In Period: Efficacy and Safety of Repeat Injections of Lorecivivint over Three Years

    Christopher Swearingen1 and Yusuf Yazici2, 1Biosplice Therapeutics, Inc, San Diego, CA, 2NYU Grossman School of Medicine, La Jolla, CA

    Background/Purpose: Lorecivivint (LOR) is an intra-articular CLK/DYRK inhibitor in clinical development for the treatment of knee OA. A Phase 3 Trial, OA-11 (NCT03928184), assessed clinical…
  • Abstract Number: 1671 • ACR Convergence 2025

    Emapalumab Treatment for Patients with Differing Presentations of Macrophage Activation Syndrome (MAS) Secondary to Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials

    Alexiei GROM1, Sebastiaan Vastert2, Jordi anton3, Pierre Quartier4, Bruno Fautrel5, Paul Brogan6, Edward Behrens7, Melissa Elder8, Francesca Minoia9, Pavla Dolezalova10, Robert Biesen11, Masaki Shimizu12, Uwe Ullmann13, Adnan Mahmood14, Andrew Danquah13, Elena Burillo13, Marco Petrimpol13, Steve Mallett15, Brian Jamieson16 and Fabrizio De Benedetti17, 1Cincinnati Children’s Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, 2University Medical Center Utrecht, Utrecht, Utrecht, Netherlands, 3Hospital Sant Joan de Düu. Universitat de Barcelona, Barcelona, Spain, 4Hôpital Necker-Enfants Malades, Paris, France, 5Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS 1136-5, PARIS, France, Paris, France, 6Great Ormond Street Hospital for Children NHS Foundation Trust and University College London Great Ormond Street Institute of Child Health, London, United Kingdom, 7CHOP, West Chester, PA, 8College of Medicine and Division of Pediatric Allergy, Immunology, and Rheumatology, Department of Pediatrics, University of Florida, GAINESVILLE, FL, 9Pediatric Immuno-Rheumatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy, 10Paediatric Rheumatology and Autoinflammatory Diseases Unit, General University Hospital, Prague, Czech Republic, 11Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, 12Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, 13Sobi, Basel, Switzerland, 14Sobi, Stockholm, Sweden, 15Sobi, Stock, Sweden, 16Sobi Inc., Morrisville, NC, 17Bambino Gesu Children's Hospital, Rome, Rome, Italy

    Background/Purpose: MAS is a life-threatening complication of Still’s disease characterized by systemic IFNg-driven hyperinflammation. Patients with Still’s disease may present with MAS at any disease…
  • Abstract Number: 1458 • ACR Convergence 2025

    Clinical Efficacy of Bimekizumab Treatment up to 2 Years Across Patients with Psoriatic Arthritis and Varying Baseline Joint Involvement: Results from a Post Hoc Analysis of Two Pooled Phase 3 Studies

    Philip J. Mease1, Laure Gossec2, Hideto Kameda3, David Nicholls4, Proton Rahman5, Barbara Ink6, Rajan Bajracharya6, Patrick Healy7 and Laura Coates8, 1Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, 2Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, 3Department of Internal Medicine, Toho University, Tokyo, Japan, 4Clinical Trials Unit, University of the Sunshine Coast, Queensland, Australia, 5Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Discipline of Medicine, Memorial University of Newfoundland, St. John's, Canada, 6UCB, Slough, England, United Kingdom, 7UCB, Morrisville, NC, 8Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom

    Background/Purpose: Patients (pts) in PsA clinical trials often have greater joint involvement than in the clinical setting due to trial inclusion criteria,1 thus it is…
  • Abstract Number: 1175 • ACR Convergence 2025

    Secukinumab In Patients with Giant Cell Arteritis with Polymyalgia Rheumatica Symptoms: A Post Hoc Analysis of the Phase 2 TitAIN Study

    Nils Venhoff1, Wolfgang Schmidt2, Raoul Bergner3, Juergen Rech4, Leonore Unger5, Stephanie Finzel6, Ioana Andreica7, David Kofler8, Stefan Weiner9, Prof. Dr. med. Peter Lamprecht10, Hendrik Schulze-Koops11, Meryl Mendelson12, Weibin Bao13, Monica Keyport14, Meron Maricos15, Valeria Jordan M.16 and Jens Thiel17, 1University of Freiburg, Freiburg, Germany, 2Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch; Waldfriede Hospital, Rheumatology, Berlin, Germany, 3Department of Internal Medicine A, Nephrology and Rheumatology, Municipal Hospital Ludwigshafen, Ludwigshafen, Germany, 4Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, 5Städtisches Klinikum Dresden, Dresden, Germany, 6Universitétsklinikum Freiburg, Freiburg im Breisgau, Germany, 7Rheumazentrum Ruhrgebiet Herne; Ruhr-Universität Bochum, Germany, Herne, Germany, 8University of Cologne, Cologne, Germany, 9Brüderkrankenhaus Trier, Trier, Germany, 10University of Lübeck, Lübeck, Germany, 11LMU Hospital, Division for Rheumatology and Clinical Immunology, Munich, Bayern, Germany, 12Novartis Pharmaceuticals, Larchmont, NY, 13Novartis Pharmaceuticals Corporation, Hanover, NJ, 14Novartis Pharmaceuticals, Stillwater, MN, 15Novartis, Nürnberg, Germany, 16Novartis Pharmaceuticals Corporation, Tenafly, NJ, 17University Hospital Freiburg, Medical University Graz, Freiburg, Germany

    Background/Purpose: GCA and PMR are closely related, immune-mediated chronic inflammatory diseases often occurring concurrently in individuals over 50.1,2 While glucocorticoids (GC) are the mainstay of…
  • Abstract Number: 0650 • ACR Convergence 2025

    Obinutuzumab Demonstrates Steroid-Sparing Effects and Consistent Benefit In Patients with Lupus Nephritis When Using Multiple Primary Endpoint Definitions: A Secondary Analysis of Phase III Trial Results

    Brad Rovin1, Jay Garg2, Richard Furie3, Rachel Jones4, Amit Saxena5, Pasquale Esposito6, Elsa Martins7, Claire Petry7, Nicolas Frey7, Bongin Yoo2, Imran Hassan8, Thomas Schindler7, Theodore Omachi9, William Pendergraft2, Mittermayer Santiago10, Gustavo Aroca Martínez11 and Ana Malvar12, 1The Ohio State University, Columbus, OH, 2Genentech, Inc., South San Francisco, CA, 3Division of Rheumatology, Northwell Health, Great Neck, NY, 4Renal Medicine, Cambridge University Hospitals, Cambridge, England, United Kingdom, 5Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, 6Clinica Nefrologica, Dialisi, Trapianto, Department of Internal Medicine, University of Genoa and IRCCS Ospedale Policlinico San Martino, Genova, Italy, 7F. Hoffmann-La Roche Ltd, Basel, Switzerland, 8Hoffmann-La Roche Ltd, Mississauga, ON, Canada, 9Genentech, Inc., South San Francisco, 10Bahiana School of Medicine and Public Health and UFBA, Federal University of Bahia, and Clínica SER da Bahia, Salvador, Bahia, Brazil, 11Universidad Simón Bolívar, Barranquilla, Colombia y Clínica de la Costa, Barranquilla, Colombia, 12Organización Médica de Investigación, Buenos Aires, Argentina

    Background/Purpose: The Phase III REGENCY study (NCT04221477) demonstrated superiority of obinutuzumab (OBI) over placebo (PBO) in achieving complete renal response (CRR) at Week 76 when…
  • Abstract Number: 0873 • ACR Convergence 2025

    Sex Differences in Proteomic Profiles and the Impact of Deucravacitinib Treatment in Patients with Active Psoriatic Arthritis: A Pooled Phase 3 Analysis

    Lihi Eder1, Shangzhong Li2, Philip J. Mease3, Christopher Ritchlin4, Walter P Maksymowych5, Hendrik Schulze-Koops6, Josef Smolen7, Oliver FitzGerald8, Vinod Chandran9, Chun Wu10 and Jinqi Liu2, 1University of Toronto, Toronto, ON, Canada, 2Bristol Myers Squibb, Princeton, NJ, 3Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, 4University of Rochester Medical Center, Canandaigua, NY, 5Department of Medicine, University of Alberta, Edmonton, AB, Canada, 6LMU Hospital, Division for Rheumatology and Clinical Immunology, Munich, Bayern, Germany, 7Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, Vienna, Austria, 8UCD, Dublin 6, Dublin, Ireland, 9Division of Rheumatology, Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto, and Gladman Krembil Psoriatic Arthritis Research Program, Krembil Research Institute, University Health Network, Toronto, Canada, 10Bristol Myers Squibb, Princeton

    Background/Purpose: PsA affects male and female patients equally; however, variations in manifestations and treatment response exist between sexes. Deucravacitinib is an oral, selective, allosteric tyrosine…
  • Abstract Number: 0488 • ACR Convergence 2025

    Early and Sustained Improvements in Disease Activity and Patient-Reported Outcomes in Patients Treated with Filgotinib for Rheumatoid Arthritis: Up to 2-Year Interim Real-World Data From FILOSOPHY and PARROTFISH

    Jérôme Avouac1, Neil Betteridge2, Karen Bevers3, Gerd Burmester4, Roberto Caporali5, Ouafia Bouzid6, Thomas Debray6, Carole Van der Donckt6, James Galloway7, Susana Romero-Yuste8 and Patrick Verschueren9, 1Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, 2Neil Betteridge Associates, London, United Kingdom, 3Sint Maartenskliniek, Nijmegen, Netherlands, 4Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 5University of Milan and ASST Gaetano Pini-CTO, Milano, Italy, 6Alfasigma S.p.A., Bologna, Italy, 7King's College London, London, United Kingdom, 8University Hospital Complex of Pontevedra, Pontevedra, Spain, 9Rheumatology, University Hospital Leuven and Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium

    Background/Purpose: FILOSOPHY (NCT04871919) and PARROTFISH (NCT05323591) are ongoing, prospective, observational Phase 4 studies of filgotinib in patients (pts) with rheumatoid arthritis (RA) in Europe. In…
  • Abstract Number: 0259 • ACR Convergence 2025

    Inhaled pirfenidone as an innovative therapeutic approach to treat autoimmune ILD and other forms of Progressive Pulmonary Fibrosis: Phase 2b Study Design

    Kristin Highland1, Colin Reisner2, Allison Trucillo3, Deepthi Nair4, Felix Woodhead4, Howard Lazarus4, Craig Conoscenti4 and Martin Kolb5, 1Cleveland Clinic, Shaker Heights, OH, 2DevPro Biopharma, Basking Ridge, NJ, 3Avalyn Pharma, Austin, TX, 4Avalyn Pharma, Cambridge, MA, 5McMaster University, Hamilton, ON, Canada

    Background/Purpose: Progressive Pulmonary Fibrosis (PPF) is an increasingly recognized condition, defined in 2022 to address the progression of pulmonary fibrosis in patients with interstitial lung…
  • Abstract Number: 2464 • ACR Convergence 2025

    IMC-002 (IMM0306), a First-in-Class Bi-specific Fusion Protein, Demonstrates Improvements in Systemic Lupus Erythematosus (SLE) Disease Activity Measures and Biomarkers in Patients with Moderate to Severe Active SLE in the Open-label Phase 1b/2 Study

    Haihong Yao1, Wenzhi Tian2, Qian Zheng2, Min Chen2, Guoping Jiang3, Zhichun Liu4, Yingkun Nie5, Rui Wu6, Zhaohui Zheng7 and Zhanguo Li1, 1Peking University People's Hospital, Beijing, China (People's Republic), 2ImmuneCare Biopharmaceuticals (Shanghai) Co.,Ltd, Shanghai, China (People's Republic), 3Jilin Province People's Hospital, Changchun, China (People's Republic), 4The Second Affiliated Hospital of Soochow, Suzhou, China (People's Republic), 5The Second Affiliated Hospital of Harbin Medical University, Haerbin, China (People's Republic), 6The First Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), 7The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China (People's Republic)

    Background/Purpose: Deep B cell depletion has been confirmed to be the main mechanism for complete clinical response of SLE patients. We analyzed the peripheral blood…
  • Abstract Number: 2347 • ACR Convergence 2025

    Bimekizumab Treatment Resulted in Patients with Axial Spondyloarthritis Maintaining Their Clinical Responses Over 3 Years: Results from Two Phase 3 Studies and Their Open-Label Extension

    Fabian Proft1, Désirée Van Der Heijde2, Sergio Schwartzman3, Vanessa Taieb4, Sarah Kavanagh5, Gaëlle Varkas6, Victoria Navarro-Compan7 and Xenofon Baraliakos8, 1Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 2Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Weill Cornell Medical Center, New York Presbyterian Hospital, and Hospital for Special Surgery, New York, NY, 4UCB, Colombes, France, 5UCB, Morrisville, NC, 6Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, 7Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, 8Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany

    Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease which requires optimal management.1 In clinical trials, Assessment of SpondyloArthritis international Society ≥40% improvement (ASAS40) is…
  • Abstract Number: 2082 • ACR Convergence 2025

    Pharmacokinetic Profile of MM-II Following a Single Intra-Articular Injection in Patients with Knee Osteoarthritis in a Phase 2b Randomized, Controlled, Dose-Ranging Trial

    Thomas Schnitzer1, Xavier Chevalier2, Helene Rovsing3, Edith Lau4, Sidsel Boll5, Ballari Brahmachari6, Richard Chou7, Tarini Joshi8, Roni Wechsler9, Sveta Weiner10, Mudgal Kothekar11, Asger Bihlet12 and Philip Conaghan13, 1Northwestern University Feinberg School of Medicine, Chicago, IL, 2Henri Mondor Hospital, University Paris XII UPEC, Créteil, France, 3Sanos Clinic, Gandrup, Denmark, 4Hong Kong Center for Clinical Research, Hong Kong, Hong Kong, 5Sanos Clinic, Vejle, Denmark, 6Sun Pharmaceuticals Industries Ltd., mumbai, Maharashtra, India, 7Sun Pharmaceutical Industries, Inc., Princeton, NJ, 8Sun Pharmaceutical Industries Limited, Mumbai, India, 9Moebius Medical, Tel Aviv, Israel, 10Sun Pharma Advanced Research Company Limited, Princeton, NJ, 11Sun Pharma Advanced Research Company Limited, Andheri (E), Princeton, NJ, 12NBCD A/S, Herlev, Denmark, 13University of Leeds, Leeds, United Kingdom

    Background/Purpose: MM-II is a first-in-class investigational treatment for knee OA pain that consists of a one-time IA injection of empty liposomes comprised of phospholipids dipalmitoylphosphatidylcholine…
  • Abstract Number: 1662 • ACR Convergence 2025

    Efficacy and Safety of Nerandomilast in Patients with Autoimmune Disease-Related Progressive Pulmonary Fibrosis: Subgroup Analysis of the FIBRONEER-ILD trial

    Anna-Maria Hoffmann-Vold1, Shervin Assassi2, Vincent Cottin3, Michael Kreuter4, Claudia Valenzuela5, Marlies S Wijsenbeek6, Hui Gu7, Ivana Ritter8, Susanne Stowasser8, Gerrit Weimann8 and Toby M Maher9, 1Oslo University Hospital, Oslo, Norway, 2Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, 3National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, UMR 754, ERN-LUNG, Lyon, France, Lyon, France, 4Center for Pulmonary Medicine, Department of Pneumology, Mainz University Medical Center and Pulmonary, Critical Care & Sleep Medicine, Marienhaus Clinic Mainz, Mainz, Germany, Heidelberg, Germany, 5Pulmonology Department, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Madrid, Spain, Madrid, Spain, 6Center of Expertise for Interstitial Lung Diseases, Department of Respiratory Medicine, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands, Rotterdam, Netherlands, 7Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, 8Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, 9Department of Pulmonary, Critical Care and Sleep Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA and Section of Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, UK, Los Angeles

    Background/Purpose: Nerandomilast is a preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory properties. The Phase III FIBRONEER-ILD trial in patients with progressive pulmonary fibrosis…
  • Abstract Number: 1455 • ACR Convergence 2025

    Sonelokimab in Patients With Active Psoriatic Arthritis Who Are Naive to Biologic DMARDs: Phase 2 ARGO Analysis and Phase 3 IZAR-1 Study Design

    Philip J. Mease1, Laure Gossec2, Atul Deodhar3, Xenofon Baraliakos4, Frank Behrens5, Joseph F Merola6, Lihi Eder7, Ana-Maria Orbai8, Andreas Ramming9, Iain McInnes10, Alexis Ogdie11, Dennis McGonagle12, Christopher Ritchlin13, Nuala Brennan14, Ben Porter-Brown14, Eva Cullen14, Matthew R. Thomas14, Marius Albulescu14, Alex Godwood14, Kristian Reich15 and Laura Coates16, 1Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, 2Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, 3Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, 4Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 5Rheumatology, Immunology - Inflammation Medicine, University Hospital Goethe-University & Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany, 6Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, 7University of Toronto, Toronto, ON, Canada, 8Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 9Department of Internal Medicine 3, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) & Universitätsklinikum Erlangen, Erlangen, Germany, 10University of Glasgow, Glasgow, United Kingdom, 11University of Pennsylvania, Philadelphia, PA, 12Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom, 13University of Rochester Medical Center, Canandaigua, NY, 14MoonLake Immunotherapeutics AG, Zug, Switzerland, 15MoonLake Immunotherapeutics AG and Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Zug, Switzerland, 16Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom

    Background/Purpose: Sonelokimab (SLK), a novel Nanobody that binds to both IL-17A and IL-17F with similarly high affinity, is designed to target difficult-to-reach sites of inflammation…
  • Abstract Number: 1172 • ACR Convergence 2025

    A Phase II, Single-Site, Open-Label Study of Zanubrutinib in Patients with IgG4-Related Disease

    Matthew Charles Baker1, Audra Horomanski2, Robert Fairchild3, Yuhan Liu3, Mariani Diaz Deluna3, Tobias Lanz4, Saurabh Gawde3, Mehdi Khalighi3, Benjamin Franc3, Mrudula Penta3, Nancy Pham3 and Kip Guja3, 1Stanford University, Menlo Park, CA, 2Stanford University, Palo Alto, CA, 3Stanford University, Stanford, CA, 4Stanford University, Stanford

    Background/Purpose: IgG4-related disease (IgG4-RD) is a chronic, systemic, immune-mediated disease that is commonly treated with B cell depletion. However, due to potential risks associated with…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 55
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology